Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Warli, Syah Mirsya, Velaro, Adrian Joshua, Firsty, Naufal Nandita, Tala, Zaimah Zulkarnaini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681786/
https://www.ncbi.nlm.nih.gov/pubmed/38022404
http://dx.doi.org/10.14740/wjon1685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681786/
https://www.ncbi.nlm.nih.gov/pubmed/38022404
http://dx.doi.org/10.14740/wjon1685

Ejemplares similares